Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis

Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection

(2019) Guoxian Zhang et al.   WORLD JOURNAL OF UROLOGY

Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations

(2019) Jing Zhang et al.   BMC CANCER

Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer

(2018) Malte Rieken et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

(2018) Izak Faiena et al.   Drug Design Development and Therapy

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification

(2018) Hui Wang et al.   MEDICINE

Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system

(2018) Hyung Suk Kim et al.   WORLD JOURNAL OF UROLOGY

Risk Stratification Tools and Prognostic Models in Non–muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel

(2018) Viktor Soukup et al.   European Urology Focus

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

(2017) Marko Babjuk et al.   EUROPEAN UROLOGY

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Shaji K. Kumar et al.   Journal of the National Comprehensive Cancer Network

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population

(2017) Kourosh Ravvaz et al.   JOURNAL OF UROLOGY

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

EORTC Risk Model to Predict Progression in Patients With Non–Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?

(2016) Wilson F.S. Busato Júnior et al.   Clinical Genitourinary Cancer

Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non–Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study

(2016) Timo Marttila et al.   EUROPEAN UROLOGY

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

(2016) Richard J. Sylvester et al.   EUROPEAN UROLOGY

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

(2016) Samantha Cambier et al.   EUROPEAN UROLOGY

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

(2016) Ashish M. Kamat et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population

(2016) Zhonghua Shen et al.   MEDICINE

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer

(2016) Jianfeng Cui et al.   MEDICINE

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1

(2016) Gilberto L. Almeida et al.   International Braz J Urol

Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours

(2014) Moniek M. Vedder et al.   PLoS One

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder

(2013) E Xylinas et al.   BRITISH JOURNAL OF CANCER

Immediate Post–Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non–Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review

(2013) Nathan Perlis et al.   EUROPEAN UROLOGY

Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder

(2013) Malte Rieken et al.   EUROPEAN UROLOGY

Predicting Recurrence and Progression in Chinese Patients With Nonmuscle-invasive Bladder Cancer Using EORTC and CUETO Scoring Models

(2013) Tianyuan Xu et al.   UROLOGY

Tratamiento del cáncer de vejiga con invasión muscular y metastásico: actualización de la Guía Clínica de la EAU

(2012) A. Stenzl et al.   Actas Urologicas Espanolas

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

(2011) Jesus Fernandez-Gomez et al.   EUROPEAN UROLOGY

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review

(2011) Sven van den Bosch et al.   EUROPEAN UROLOGY

Do Standardised Prognostic Algorithms Reflect Local Practice? Application of EORTC Risk Tables for Non-Muscle Invasive (pTa/pT1) Bladder Cancer Recurrence and Progression in a Local Cohort

(2011) Rajiv Pillai et al.   TheScientificWorldJOURNAL

External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

(2010) Virginia Hernández et al.   WORLD JOURNAL OF UROLOGY

Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy

(2009) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

(2009) Jesus Fernandez-Gomez et al.   JOURNAL OF UROLOGY

Nomograms for Prediction of Disease Recurrence in Patients with Primary Ta, T1 Transitional Cell Carcinoma of the Bladder

(2008) Sung Joon Hong et al.   JOURNAL OF KOREAN MEDICAL SCIENCE